OTC:CRFTF) (
FSE:ZZD1) announces that further to the news release issued on January 18, 2021, it has entered into a definitive agreement dated March 4, 2021 (the “
Definitive Agreement”), to acquire 100% of the issued and outstanding shares of Ava Pathways Inc. (“
Ava Pathways”), from arm’s length parties (the “
Acquisition”).
Based in Vancouver, BC, Ava Pathways is an innovative company that is exploring the therapeutic scientific benefits of proprietary formulations, using compounds from mushrooms. Ava Pathways was founded by scientists and researchers focused on neuroplasticity and alternative ways to treat common and debilitating medical conditions such as depression, anxiety, PTSD, and substance use disorder, through the use of psychedelic-based treatments. Similar to craft cannabis, both plant-based treatments require a cultivation supply network to create proprietary strains that produce optimal results for the patient or end-user. Ava Pathways brings except